Page 80 - Read Online

García-Pardo et al. J Cancer Metastasis Treat 2021;7:62 https://dx.doi.org/10.20517/2394-4722.2021.103 Page 17 of 22

Copyright
© The Author(s) 2021.

REFERENCES
1. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat
Rev Cancer 2010;10:37-50. DOI PubMed
2. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012;122:3432-8. DOI
PubMed PMC
3. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet 2018;391:1524-37. DOI PubMed
4. Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic
strategies. Haematologica 2020;105:2205-17. DOI PubMed PMC
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood
1975;46:219-34. PubMed
6. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate
survival analysis. Cancer 1981;48:198-206. DOI PubMed
7. Eichhorst B, Robak T, Montserrat E, et al; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:23-33. DOI PubMed
8. Fürstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome
resistance. Cancers (Basel) 2021;13:1336. DOI PubMed PMC
9. Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med
2012;209:2183-98. DOI PubMed PMC
10. Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic
lymphocytic leukemia. J Clin Oncol 2014;32:897-904. DOI PubMed PMC
11. Burgler S. Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic
target. Crit Rev Immunol 2015;35:417-32. DOI PubMed
12. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Nature 2011;475:101-5. DOI PubMed PMC
13. Benedetti D, Tissino E, Pozzo F, et al. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic
leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia 2018;32:654-62. DOI PubMed
14. Davids MS, Burger JA. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol 2012;3:1. DOI PubMed PMC
15. Redondo-Muñoz J, García-Pardo A, Teixidó J. Molecular players in hematologic tumor cell trafficking. Front Immunol 2019;10:156.
DOI PubMed PMC
16. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later.
Blood 2011;118:3470-8. DOI PubMed PMC
17. Gutjahr JC, Greil R, Hartmann TN. The role of CD44 in the pathophysiology of chronic lymphocytic leukemia. Front Immunol
2015;6:177. DOI PubMed PMC
18. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into
disease biology and new targeted therapies. Semin Cancer Biol 2014;24:71-81. DOI PubMed
19. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood
2000;96:2240-5. PubMed
20. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic
lymphocytic leukemia. Semin Oncol 2006;33:174-85. DOI PubMed
21. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer
2006;107:925-34. DOI PubMed
22. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia
2000;14:1414-8. DOI PubMed
23. Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001;97:2529. DOI PubMed
24. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC. Dysregulated angiogenesis in B-chronic lymphocytic
leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 2008;3:16. DOI PubMed PMC
25. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is
associated with differential regulation of angiogenic factors. Leukemia 2009;23:162-9. DOI PubMed
26. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic
leukemia. Blood 2002;100:3344-51. DOI PubMed
27. Molica S, Cutrona G, Vitelli G, et al. Markers of increased angiogenesis and their correlation with biological parameters identifying
high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res 2007;31:1575-8. DOI PubMed
28. Ding W, Nowakowski GS, Knox TR, et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication
for CLL disease progression. Br J Haematol 2009;147:471-83. DOI PubMed PMC
29. Attekum MH, Eldering E, Kater AP. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.
Haematologica 2017;102:1469-76. DOI PubMed PMC
30. Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B. Importance of crosstalk between chronic lymphocytic